Molnupiravir Global Market Report 2023: Rising Instances of COVID-19 Drives Growth

Dublin, March 08, 2023 (GLOBE NEWSWIRE) -- The "Molnupiravir Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Application (Influenza, Ebola, COVID-19, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region" report has been added to's offering.

The Global Molnupiravir market may register impressive growth in the forecast period, 2023-2027, due to rising demands for effective pharmaceuticals for the rising cases of COVID-19. The high prevalence of the disease coupled with the viral variant complicates the conditions of the patients and thus leading to severe conditions of the infection and causing death for the population, driving the growth of the global Molnupiravir market in the upcoming five years.

Furthermore, increasing research and development activities by various pharmaceutical & biotechnology players for the development of potential antiviral drugs is anticipated to foster market growth.

Molnupiravir is an orally bioavailable form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV2, the causative agent of COVID-19. In simpler terms, the pharmaceutical product Molnupiravir is an orally administered drug that has higher potency as compared to other antiviral drugs against COVID-19. The drug has the chemical composition of mRNA that can act against the viral, and COVID infection-causing virus' RNA. This RNA sequence has an effect against the new SARS-CoV2 too is thus used for controlling the effects of COVID-19.

Rising Instances of COVID-19 Drives Market Growth

Growing instances of COVID-19-positive cases are a major factor driving the growth of the global Molnupiravir market in the upcoming five years. Although through effective vaccinations and the use of precautionary steps, the rapid growth in the cases has been controlled. Although, growing variants of the virus and its evolving effect on the human body affect lives, and thus the demand for efficient pharmaceuticals such as Molnupiravir increases thereby supporting the growth of the global Molnupiravir market in the next five years.

As of 24th May 2022, there are already 528.37 million COVID-19 cases around the world, out of which 85.11 million cases belong to the United States itself. With the viral infection affecting such a large population in the country, the United States government had hastily authorized the administration of Molnupiravir to patients suffering from the mild symptoms of COVID-19. The orally administered capsules had certain concerns and side effects in their early phase-outs. Soon followed by the affordability of the drug as compared to other available treatment drugs, the industry for the drug expanded and with Clinical Phase III human trials already approved, the drug is expected to substantially grow in the forecast years.

Investments & Advancement Wheel In Further Market Growth

Rising investment in the pharmaceutical industry and growing expenses from the consumers toward effective drug development and overcoming the disease drives the growth of the global Molnupiravir market in the upcoming five years. Consumers are eager to adapt to more advanced, highly effective, and efficient drugs. If these drugs are affordable and are available in the local pharmaceutical markets, the distribution channel efficiency further fuels the growth of the global Molnupiravir market in the next five years.

In 2021, more than 3 million courses of Molnupiravir were supplied to the U.S. government within approximately 7 weeks of receiving emergency use authorization from the U.S. food and drug administration. The demands for drugs are high in the North American region looking at the growing instances of the cases in the country. Further evolutions in other pharmaceuticals and advancements in the innovative COVID-19 restricting drugs may create restraint on the growth of the market.

Report Scope:

In this report, global Molnupiravir market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Molnupiravir Market, By Type:

  • Influenza
  • Ebola
  • COVID-19
  • Others

Molnupiravir Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Molnupiravir Market, By Region:

  • North America
  • United States
  • Mexico
  • Canada
  • Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Vietnam
  • Philippines
  • Indonesia
  • Malaysia
  • Europe
  • France
  • Germany
  • United Kingdom
  • Spain
  • Italy
  • Denmark
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kenya

Key Topics Covered:

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Molnupiravir Market

4. Executive Summary

5. Voice of Customer

6. Pharmacodynamic Overview of Molnupiravir

7. Clinical Trials

8. Patent Analysis

9. Global Molnupiravir Market Outlook

10. North America Molnupiravir Market Outlook

11. Europe Molnupiravir Market Outlook

12. Asia-Pacific Molnupiravir Market Outlook

13. South America Molnupiravir Market Outlook

14. Middle East and Africa Molnupiravir Market Outlook

15. Market Dynamics

16. Market Trends & Developments

17. Competitive Landscape

18. Strategic Recommendations

A selection of companies mentioned in this report includes

  • Merck Sharp & Dohme Corp.
  • Everest Organics Limited
  • Optimus Drugs Pvt Ltd.
  • Dr. Reddy's Laboratories Ltd
  • Cipla Limited
  • Mylan N.V.
  • Emcure Pharmaceuticals Ltd.
  • Sun Pharmaceutical Industries Limited
  • Hetero Drugs Ltd.
  • Torrent Pharmaceuticals Ltd.

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Contact Data